Improving glucocorticoid replacement therapy using a novel modified-release hydrocortisone tablet: a pharmacokinetic study.
Autor: | Johannsson G; Department of Endocrinology, Sahlgrenska Academy, Sahlgrenska University Hospital, Grona Straket 8 Clinical Pharmacology, Sahlgrenska Academy, Gothenburg University, SE-413 45 Gothenburg, Sweden. gudmundur.johannsson@gu.se, Bergthorsdottir R, Nilsson AG, Lennernas H, Hedner T, Skrtic S |
---|---|
Jazyk: | angličtina |
Zdroj: | European journal of endocrinology [Eur J Endocrinol] 2009 Jul; Vol. 161 (1), pp. 119-30. Date of Electronic Publication: 2009 Apr 21. |
DOI: | 10.1530/EJE-09-0170 |
Abstrakt: | Background: Endogenous plasma cortisol levels have a well-defined circadian rhythm. The aim of this project is to develop a once daily oral dual-release formulation for cortisol replacement therapy that mimics the diurnal variation in the plasma cortisol profile. Objective: To determine single-dose plasma pharmacokinetics and dose-proportionality of oral 5 and 20 mg dual-release hydrocortisone tablets in healthy volunteers. In addition, the effect of food intake was investigated for the 20 mg dose. Design: A randomised, controlled, two-way cross-over, double-blind, phase I study of oral hydrocortisone (modified (dual) release; 5 and 20 mg) with an open food-interaction arm. Methods: The single dose pharmacokinetic studies were performed with betamethasone suppression. The two first study days were blinded and randomised between morning administration of 5 and 20 mg tablet in a fasting state. The third day was open with a 20 mg tablet taken 30 min after a high-calorie, high-fat meal. The plasma samples were assayed using both a validated LC-MS/MS and an immunoassay. The plasma pharmacokinetic variables were calculated using non-compartmental data analysis. Results: The time to reach a clinically significant plasma concentration of cortisol (>200 nmol/l) was within 20 min and a mean peak of 431 (s.d. 126) nmol/l was obtained within 50 min after administration of the 20 mg tablet. Plasma cortisol levels remained above 200 nmol/l for around 6 h thereafter and all plasma concentrations 18-24 h after intake were below 50 nmol/l. In the fed state the time to reach 200 nmol/l was delayed by 28 and 9 min based on LC-MS/MS and immunoassay, respectively. The 5 and 20 mg tablets produced an increase in plasma exposure of cortisol that was not fully dose proportional. Conclusion: The dual release hydrocortisone tablet with once-daily administration produced a diurnal plasma cortisol profile mimicking the physiological serum cortisol profile. |
Databáze: | MEDLINE |
Externí odkaz: |